RxDoctor Payments DataLook up a doctor →

Joseph la Conti

Rheumatology · Miami, FLNPI 1831465954

Payments from drug & device makers

$661,238in general payments, 2019–2025

Across 1,208 payments — averaging $547.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$292K
  • AbbVie$242K
  • GSK$85K
  • Eli Lilly$19K
  • Johnson & Johnson$6K
  • UCB SA$6K
  • plus $11K from 37 others

What the payments were for

  • Consulting fees$8,4452%
  • Speaking & faculty fees$279,28881%
  • Grants$2400%
  • Travel & lodging$32,7839%
  • Food & beverage$24,6487%
  • Education$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$661,238 in reported general payments places this provider in the 90th percentile of 453 rheumatology providers in Florida.

See all rheumatology providers in Florida

Medicare billing

Part B allowed, 2024
$1,370,254
Medicare patients
448
Services billed
114,156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KrystexxaPegloticase12$457,777
Humira(Cf) PenAdalimumab57$433,357
RinvoqUpadacitinib31$255,715
BenlystaBelimumab46$234,324
OfevNintedanib Esylate14$185,586
XeljanzTofacitinib Citrate22$135,775
EnbrelEtanercept15$130,800
Actemra ActpenTocilizumab24$128,310
OtezlaApremilast19$100,929
ProliaDenosumab61$98,627
Orencia ClickjectAbatacept11$61,642
OlumiantBaricitinib15$41,652
RasuvoMethotrexate/Pf27$19,663
Hydroxychloroquine Sulfate401$14,289
LovazaOmega-3 Acid Ethyl Esters11$12,702

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenKrystexxa, Enbrel, Otezla, Prolia$2,423$788,133107 claims
AbbVieRinvoq$241,935$255,71531 claims
GSKBenlysta$84,694$234,32446 claims
Boehringer IngelheimOfev$861$185,58614 claims
PfizerXeljanz$288$135,77522 claims
Lilly USA, LLCOlumiant$456$41,65215 claims
Medexus Pharma, Inc.Rasuvo$13$19,66327 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 453 rheumatology providers in Florida.

Other rheumatology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →